Groowe / Newsroom / ELDN

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ELDN News

Eledon Pharmaceuticals, Inc. Common Stock

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

globenewswire.com Oct 17, 2025 1:06 PM